ReviewFrontiers in oncology2022
Selective depletion of naïve T cells by targeting CD45RA.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06839456 (Phase 1/2 Study), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant
Who cites it
10 citing papers in PubMed.
- Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial.Journal of hematology & oncology · 2024Trial
- Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RAGeroScience · 2026Article
- Cellular therapies for the prevention and treatment of acute graft-versus-host disease.Stem cells (Dayton, Ohio) · 2025Review
- Altered CD27-related T cell subsets reflect immune imbalance in systemic lupus erythematosus.Immunologic research · 2025Article
- Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.Frontiers in immunology · 2025Review
- Novel conditioning and prophylaxis regimens for relapse prevention.Hematology. American Society of Hematology. Education Program · 2024Review
- Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis.Science translational medicine · 2024Review
- Review
- Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy.Frontiers in molecular medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.